Requip Tablets 2 mg (Ropinirole Hydrochloride)

Adult dose

1. An individualized optimal dose is recommended based on efficacy and tolerability. (1) Idiopathic Parkinson's disease It is preferable to take this drug with food three times daily to improve gastrointestinal tolerability. Initial therapy: Take 0.25mg 3 times daily. The treatment regimen for the first 4 weeks is as follows: Week 1: Dose per administration 0.25mg, daily dose 0.75mg Week 2: Dose per administration 0.5mg, daily dose 1.5mg Week 3: Dose per administration 0.75mg, daily dose 2.25mg Week 4: Dose per administration 1.0mg, daily dose 3.0mg Maintenance therapy: After initial therapy, the daily dose may be increased at 1-week intervals up to 3mg daily. Therapeutic effects are seen at 3-9mg daily. If symptoms are not adequately controlled or control is not maintained, the ropinirole dose may be increased until a clear therapeutic effect is achieved, but should not exceed 24mg daily. ① When administered as adjunctive therapy to levodopa, the levodopa dose may be gradually reduced by up to approximately 20% of the total dose. ② When switching from another dopamine agonist to ropinirole, follow the manufacturer's guidance on discontinuation before administering ropinirole. ③ As with other dopamine agonists, when discontinuing ropinirole, gradually stop it by reducing the number of daily administrations over 1 week. (See “4. General precautions” under Precautions for use.) (2) Primary restless legs syndrome Ropinirole should be taken once daily before bedtime, 1~3 hours before bedtime. Initial therapy (week 1): The initial recommended dose is 0.25mg once daily for 2 days, taken 1~3 hours before bedtime. If this dose is well tolerated, it may be increased to 0.5mg once daily starting on day 3 through the last day of the first week of treatment (day 7 of administration). Maintenance therapy (from week 2): After initial therapy, the daily dose may be increased according to the following schedule until the optimal therapeutic response is achieved. Week 2: Dose per administration 1mg Week 3: Dose per administration 1.5mg Week 4: Dose per administration 2mg Week 5: Dose per administration 2.5mg Week 6: Dose per administration 3mg Week 7: Dose per administration 4mg The safety and efficacy of doses above 4mg/day in patients with restless legs syndrome have not been established. As with other dopamine agonists, treatment with this drug should be discontinued gradually while reducing the daily dose. (See “4. General precautions” under Precautions for use.) If administration of this drug has been interrupted significantly, it is recommended that treatment be restarted using the dose titration described above. 2. Patients with renal impairment: Since ropinirole clearance is unchanged in patients with mild or moderate renal impairment (creatinine clearance 30-50mL /min), dose adjustment is not required. Use of this drug has not been studied in severe renal impairment (creatinine clearance ＜30mL/min); therefore, ropinirole is not recommended in these patients. 3. Patients with hepatic impairment: Use of this drug has not been studied in patients with hepatic impairment; therefore, ropinirole is not recommended in these patients. 4. Use in elderly patients: Ropinirole clearance decreases in patients aged 65 years and older, but the dose in elderly patients may be adjusted in the usual manner according to the patient's clinical response.

Child dose

Do not administer to children.

This drug is a dopamine agonist and caution is required in patients with severe cardiovascular diseases. In particular, when used with medications that lower blood pressure or treat arrhythmias, it may lead to heart problems such as hypotension or bradycardia. It should only be used in patients with severe mental disorders when the benefits of treatment outweigh possible risks. Sudden drowsiness or sleep may occur while taking this medication, so activities that require alertness, such as driving or operating machinery, should be avoided if drowsiness is severe. Patients who have hypersensitivity to this medication, women who are pregnant or breastfeeding, and patients with lactose intolerance should not take this drug. Various side effects such as nausea, vomiting, drowsiness, dizziness, hypotension, and swelling may occur, and if symptoms are severe, dosage adjustments should be discussed with a doctor. In particular, patients with Parkinson's disease may exhibit neurological side effects such as dyskinesia or hallucinations and confusion, which should be monitored carefully. It is not advisable to use this medication in combination with other dopamine agonists, and if you are taking other medications, you must inform your doctor due to potential interactions. It may be harmful to the fetus during pregnancy and can suppress milk secretion during breastfeeding, so it should not be used. Its safety and efficacy in children under 18 years have not been established, so it is not recommended. In the case of overdose, serious symptoms such as nausea, hallucinations, hypotension, and drowsiness may occur, requiring immediate medical attention. Store in a cool, dry place out of the reach of children.

• Nausea
• drowsiness
• leg edema
• abdominal pain
• vomiting
• fainting
• movement disorders
• hallucinations
• confusion
• dizziness

Store this medication in a cool place below 25 degrees Celsius, in a tightly sealed container protected from light. This will help maintain the efficacy of the medication over time.

Appearance

Light yellow pink film-coated tablets in a pentagonal shape, convex on both sides, engraved with 'SB' on one side and '4893' on the other side.

Package unit

21 tablets/PTP